Journal paper weighs GLP-1 to tirzepatide switching in diabetic fatty liver disease

The wire

1. 01Patoulias and colleagues examine whether therapeutic sequencing matters when patients with type 2 diabetes switch from a GLP-1 receptor agonist to tirzepatide and also have metabolic dysfunction-associated steatotic liver disease.
2. 02Switching between incretin agents is a routine clinical decision, and liver outcomes are an increasingly common consideration in that choice.
3. 03Only the title and citation are available; readers should check the full text for whether the analysis rests on trial data or commentary.

From the source

Switching from glucagon-like peptide-1 receptor agonists to tirzepatide in type 2 diabetes: does therapeutic sequencing matter for metabolic dysfunction-associated steatotic liver disease?

Journal of diabetes and its complications · 2026 Sep 18 · Patoulias D, Muzurović E, Rizzo M et al.